NASA Successfully Demonstrates rHEALTH’s Powerful Biomedical Analyzer Onboard Space Station in a First for Space Medicine
The demo in space tested the rHEALTH ONE universal biomedical analyzer for its ability to precisely measure tiny samples in microgravity.
Bedford, MA, May 23, 2022. rHEALTH today announced that, in partnership with NASA, that its rHEALTH ONE universal biomedical analyzer was successfully demonstrated on-orbit at the International Space Station. Samantha Cristoforetti, the ESA astronaut part of the SpaceX Crew-4 astronaut team, demonstrated first in space operation of the sophisticated biomedical analyzer. She performed experiments across two sessions involving microliter drops of NASA-prepared control samples on May 13, 2022 between 09:00 and 17:00 GMT and again on May 16, 2022 between 10:45 and 18:30 GMT.
The rHEALTH ONE is the most powerful biomedical analyzer successfully tested onboard the space station. It made several firsts with the demonstration. It was the first biomedical analyzer to demonstrate in space the principles of solid-state, sheath-flow focused cytometry. With its optical block technology, it was the first to demonstrate two-lasers, five simultaneous data channels, allowing a new type of dense biological data collection in microgravity. Close to 100 million raw data points, sampled in microsecond time intervals, were collected with each run, which lasted a few minutes each. It was the first to demonstrate a patented in-line microvolume sample loading mechanism for small sample drops, each less than 10 microliters. This mechanism allows for repeated sample loading of scant biological samples in microgravity.
The technical achievement provides new potential capabilities for the space community, including diagnosis and monitoring of spaceflight medical conditions, such as radiation exposure, circadian rhythm disorders, bone loss, and kidney stones. Enabling research studies for these conditions can also be performed directly on-orbit without need for sample downmass, which requires samples to be stored in suboptimal conditions for long-periods of time prior to analysis. Future deep-space exploration missions provide further complex challenges, including limitations in mass, volume, and power for devices and inability to return samples back to Earth for analysis. The rHEALTH technology fulfills this critical need by having broad capabilities to measure cells, cell counts, biomarkers, microorganisms, electrolytes, and enzymes for various sample types, include blood and other bodily fluids.
“This is a remarkable accomplishment on so many different levels, only possible with close collaboration of so many exceptional teams. The demonstration solidifies our belief that the spaceship is a microcosm for our households; each is its own self-contained entity in need of direct access to healthcare,” said Eugene Chan MD, Founder and CEO of rHEALTH.
About rHEALTH
rHEALTH is a company focused on the development and commercialization of its Your Health, AnywhereTM technology. The rHEALTH blood sensor is the subject of multiple XPRIZE awards, NASA contracts, and over a dozen issued patents. The payload was developed with various groups at NASA, ZIN Technologies, and rHEALTH. For more information, visit www.rhealth.com.
NASA Launches rHEALTH Blood Analyzer to International Space Station
rHEALTH ONE small volume blood analyzer arrived at International Space Station on Feb. 21.
Bedford, MA, February 22, 2022. rHEALTH, announced today that NASA has successfully launched its rHEALTH ONE blood analyzer to space on NASA Commercial Resupply Mission NG-17. The rHEALTH ONE was carried to the International Space Station (ISS) via the NG-17 Cygnus spacecraft, launched by a Northrop Grumman Antares Rocket. The rocket was successfully launched off the Mid-Atlantic Regional Spaceport (MARS) Pad 0A on Wallops Island, Virginia, shortly after noon on February 19. The path to the space station included a two-stage rocket launch, with the first stage being approximately three and half minutes, a second-stage burn for two and a half minutes, and then a 2 day transit to the ISS.
The rHEALTH ONE is a universal biomedical analyzer which can analyze a diversity of biomedical analytes from a small drop (8 microliters) of blood, urine, swabs, or other biological fluids. The capabilities of the rHEALTH technology spans a breadth of assay classes, including cell counts, chemistry, small molecules, biomarkers, and nucleic acids. In space, lack of medical assistance, confined environments and real-time communications can exacerbate the challenges in responding to medical emergencies. There is a real and pressing need to obtain medical and research diagnostic information quickly and easily for long-duration space travel. NASA’s aim for the technology is to further advance its readiness by showing operation in a real space-environment and provide real terrestrial benefits for all of us.
Present at the launch, Eugene Chan MD, CEO and inventor of the rHEALTH technology said, “This is a marvel of a long collaboration with NASA. The device is designed to provide both comprehensive health information for astronauts while travelling to Mars and accessible autonomous health for all on Earth.”
The technology will be operated by NASA astronauts for the technology demonstration in the coming months.
About rHEALTH
rHEALTH is a company focused on the development and commercialization of its Your Health, AnywhereTM technology. The rHEALTH blood sensor is the subject of multiple XPRIZE awards, NASA contracts, and over a dozen issued patents. For more information, visit www.rhealth.com.
rHEALTH ONE to be Launched to Space Feb. 19.
Launch viewing instructions and details below
The rHEALTH ONE blood analyzer will be sent to the International Space Station (ISS) by NASA on February 19, 2022 12:39 PM ET from Wallops Island, Virginia. The launch will be on a Northrop Grumman Antares Rocket, carrying a NG-17 Cygnus spacecraft.
The launch can be viewed in person:
Launch coverage and mission commentary will air on NASA TV at 12:15 p.m. For NASA TV streaming video, downlink and scheduling information, visit:
Other interesting links relating to the launch:
NG-17-Mission-Profile-Handout.pdf (northropgrumman.com)
NASA Commercial Resupply Mission NG 17 - Northrop Grumman
rHEALTH and Global BioPharmaceutical Company Developed Prototype Point-of-Care Test for Thrombocytopenia
Approach is used to measure low platelets, a side-effect of vaccine and medications
Bedford, MA, August 30, 2021. rHEALTH today announced that, in partnership with a global pharma company, it has developed and demonstrated a highly accurate, fingerstick-based approach to measuring thrombocytopenia, or low platelet counts. The approach, as published in PloS ONE, a peer-reviewed open access journal published by the Public Library of Science, is titled, “Point-of-care microvolume cytometer measures platelet counts with high accuracy from capillary blood.” The details of the work and authorship are here.
Thrombocytopenia is a side-effect of adenovirus-based vaccines, chemotherapy drugs, and characteristic of idiopathic thrombocytopenic purpura. Accurate measurements of low platelets, below 75,000 platelets/uL, are required to diagnose thrombocytopenia. For gold-standard measurements, large central lab equipment and venous blood draws performed by phlebotomists are required. Conventional approaches are thus not suitable for widespread screening of individuals at-risk of thrombocytopenia. Ideally, as described in the work, the approach utilizes a fingerstick blood sample, obtained with a lancet, which can be performed at home and other non-hospital settings. The measurements should be performed on a small, portable device, such as the rHEALTH ONE used for the study.
“The rHEALTH technology shows that thrombocytopenia can be diagnosed accurately with our minimally invasive, point-of-care approach. It has the potential to provide optimal patient care for those at risk of thrombocytopenia,” said Eugene Chan MD, CEO of rHEALTH.
The study showed that the rHEALTH method can successfully measure 8 μL of sample, derived from fingerstick capillary blood collected and tested by trained laboratory professionals, to achieve platelet counts comparable to the gold-standard International Society for Laboratory Hematology method. Very strong correlation between the two methods was observed for low and normal platelet counts. An important step towards the development of the point-of-care assay is for at-home use.
About rHEALTH
rHEALTH is a company focused on the development and commercialization of its Your Health, AnywhereTM technology. The rHEALTH blood sensor is the subject of multiple XPRIZE awards, a NASA effort for astronaut health monitoring, and over a dozen issued patents. The work for the study was funded by the global pharma company described here and the National Heart, Lung, Blood Institute of the National Institutes of Health under award R44 HL099092. For more information, visit www.rhealth.com.
rHEALTH’s Category Leading Vital Signs Device Granted US Patent
United States Patent and Trademark Office (USPTO) grants patent for continuous, pan-vitals monitoring technology designed for astronauts and airmen
BEDFORD, Mass., July 22, 2021 – rHEALTH LLC, a Diagnose Yourself, AnywhereTM company, and its affiliate DNA Medicine Institute, Inc., announced today its SKYE Sensor has been granted US Patent 10,918,290 B2. The device is a chest-worn device which allows for continuous monitoring of all important vital signs: EKG, oxygen saturation, heart rate, core body temperature, and cuffless blood pressure. The device is the first device to integrate all these critical vital signs and be able to measure them continuously. The SKYE Sensor is paired with an app so it can be used anywhere.
The SKYE Sensor was developed in a joint collaboration between the National Aeronautics and Space Administration (NASA) and the United States Air Force as an ideal approach for optimizing astronaut and airmen performance under extreme conditions. Both groups consists of individuals who have to pass extremely rigorous physical tests. The SKYE Sensor allows for monitoring performance over long-durations under sleep deprivation, circadian rhythm disturbances, extravehicular activity, and zero gravity.
“The SKYE Sensor is a single transformative device that allows users the ability to continuously monitor their vital signs under extreme conditions. This is of paramount importance for medical monitoring and assessing optimal human health and performance,” said Eugene Chan MD, CEO of rHEALTH.
The device is worn on the upper torso with an adhesive pad or a flexible, comfortable strap. Battery life is 12 hours to 2 weeks, depending on which vital signs are being monitored. It comes with a USB-based charging dock and an app which serves as a dashboard. It is features innovative multi-mode sensors that provide low-powered, wireless, pan-sensing capabilities.
About rHEALTH®
rHEALTH is a company focused on the development and commercialization of its Diagnose Yourself, AnywhereTM technology. The rHEALTH blood sensor is the subject of multiple XPRIZE awards, a NASA effort for astronaut health monitoring, and over a dozen issued patents. The SKYE Sensor is meant to provide comprehensive, continuous vitals monitoring under a wide range of conditions. For more information, visit www.rhealth.com.
About DNA Medicine Institute
DNA Medicine Institute (DMI) is a biomedical incubator focused on advancing patient care, alleviating human suffering, and treating disease through innovation. Its technology is subject of work funded by NASA, National Institutes of Health, and the Bill & Melinda Gates Foundation. DMI leverages substantial expertise in interdisciplinary science and engineering to solve challenging problems. For more information, visit www.dnamedinstitute.com. The interagency collaboration for development of the SKYE Sensor was administered by NASA under contracts 80NSSC18P0210 and NNX15CJ08C.
Media Contact
Press Releases, (617) 913-7630, pr@rhealth.com
rHEALTH Receives NIH RADx Funding to Advance Its Point-of-Care COVID Antigen Test for Schools, Businesses, and Group Settings
New Biden administration supports broadened testing efforts
BEDFORD, Mass., April 2, 2021 – rHEALTH LLC, a Diagnose Yourself, AnywhereTM company, today announced that it has received funding support to advance its diagnostic technology from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) Tech program. The award is managed by Consortia of Improving Medicine with Innovation & Technology (CIMIT) and the NIH Point-of-Care Technologies Research Network (POCTRN), will be leveraged to oversee and help guide development, validation, and further advancement of rHEALTH’s app-guided, user-friendly, high-sensitivity layperson antigen test. rHEALTH received the support after being vetted through a “Shark Tank”-like selection process.
The antigen test runs on a high-performance, user-friendly point-of-care analyzer called the rHEALTH, a patented, award-winning device funded by the NIH and NASA. A consumer-tested app guides the user through the testing sequence, which features minimal user touch points, and provides a result within 15 minutes for the user. The solution is differentiated in its ease-of-use, pandemic-mode throughput, and a high-sensitivity, cocktail-based antibody assay. The cocktail approach is designed to future-proof the technology against emerging variants.
“We are committed to working with the NIH to enhance efforts to diagnose COVID-19 in all settings. We aim to allow teachers, business owners, nursing home staff, and others to have more tools against the virus. The availability of a rapid, point-of-care antigen test for anyone to use is a particularly important means to attain widespread testing. Success of this approach means that these places with children, employees, seniors, and travelers will have greater safety, immediately,” said Eugene Chan M.D., CEO of rHEALTH.
Launched in April 2020, the NIH RADx initiative received an initial $1.5 billion federal investment and has been an urgent call for science and engineering’s most inventive and visionary minds to develop rapid, easy-to-use technology technologies for SARS-CoV-2, the novel coronavirus that causes COVID-19. In a September 2020 NIH news announcement regarding projects funded through the RADx initiative, NIH Director Francis S. Collins, M.D., Ph.D. said, “Diagnostic testing is a critical component of the nation’s strategy to meet the challenge of the COVID-19 pandemic.”
CIMIT and POCTRN are supported by the RADx Tech program and have been funded in part with federal funds from the National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Department of Health and Human Services, under Grant No. U54EB015408.
About rHEALTH®
rHEALTH is a company focused on the development and commercialization of its Diagnose Yourself, AnywhereTM technology. The rHEALTH technology is the subject of multiple XPRIZE awards, a NASA effort for astronaut health monitoring, and over a dozen issued patents. It enables diverse laboratory tests from a single tiny sample. rHEALTH has received support from CIMIT through the POCTRN program. For more information, visit www.rhealth.com.
Media Contact
Press Releases, (617) 913-7630, pr@rhealth.com
rHEALTH’s FVIII Point-of-Care Device Awarded $1.5M Direct-to-Phase II Grant from the NIH
Grant supports efforts to utilize rHEALTH’s point-of-care technology for monitoring FVIII and emicizumab levels in hemophilia A patients
BEDFORD, Mass., October 8, 2020 – rHEALTH LLC, a Diagnose Yourself, AnywhereTM company, today announced that its technology is the subject of the award from the National Institute of Health (NIH). The award is to rHEALTH’s affiliate, the DNA Medicine Institute (DMI), which has granted rHEALTH commercial rights to the technology. The focus of the grant is to further develop the company’s fingerstick-based point-of-care technology for monitoring both FVIII and emicizumab. rHEALTH’s solution takes a tiny blood sample and provides a result in 15 minutes for a patient or medical provider via its app-driven, Bluetooth-connected interface. Conventional central lab FVIII testing require large machines and is difficult to perform. Because of this, hemophilia is greatly underdiagnosed in many countries around the world. Lack of proper testing instruments and materials make both diagnosis and management of bleeding episodes and surgeries very challenging.
Two distinguished collaborators, the World Federation of Hemophilia (WFH) and Boston Children’s Hospital (BCH) are part of the effort. WFH is an international non-profit organization dedicated to improving the lives of people with genetic bleeding disorders. They will work with rHEALTH to plan field-based studies of the device in the developing world. BCH is the US News & World Report’s #1 pediatric hospital in the US and routinely treats hemophilia A patients. Their interest is to benchmark the performance of the device against its lab analyzers and to provide more accessible testing for its patients.
“The rHEALTH point-of-care technology has the potential to impact the diagnosis and monitoring of hemophilia A worldwide,” said Alain Baumann, CEO of WFH. “An easy-to-use approach for monitoring FVIII and emicizumab will improve patient care through widening availability of testing, which is today complex and hospital-based,” said Glenn Pierce MD PhD, VP of Medical of WFH.
“We are intent on advancing testing for hemophilia patients, who deserve an easy-to-use technology for managing their condition,” said Eugene Chan MD, CEO of rHEALTH. The rHEALTH device is an award-winning, patented technology. For FVIII measurements, it utilizes the chemistry in rHEALTH’s CE-marked two-stage fluorogenic assay to provide highly accurate results from < 1% to 200% levels.
About rHEALTH®
rHEALTH is a company focused on the development and commercialization of its Diagnose Yourself, AnywhereTM technology. The rHEALTH blood sensor is the subject of multiple XPRIZE awards, a NASA effort for astronaut health monitoring, and over a dozen issued patents. It enables diverse laboratory tests from a single tiny blood sample. For more information, visit www.rhealth.com.
About DNA Medicine Institute
DNA Medicine Institute (DMI) is a biomedical incubator focused on advancing patient care, alleviating human suffering, and treating disease through innovation. Its technology is subject of work funded by NASA, National Institutes of Health, and the Bill & Melinda Gates Foundation. DMI leverages substantial expertise in interdisciplinary science and engineering to solve challenging problems. For more information, visit www.dnamedinstitute.com.
Media Contact
Press Releases, (617) 913-7630, pr@rhealth.com
rHEALTH Attains ISO 13485 Certification and Announces Facilities Expansion
Certification conforms to worldwide standard for medical device quality and together with the expansion, allows rHEALTH to meet its commercial objectives
BEDFORD, Mass., April 22, 2020 – rHEALTH LLC, a Diagnose Yourself, AnywhereTM company, today announced that it has received ISO 13485:2016 certification for the design and development, production and distribution, and servicing of in vitro diagnostic devices (IVD), kits, reagents, analyzers, and software. Concurrently, it announced expansion to a 22,000 square feet facility in Bedford, MA, which was inspected during the certification process and will support its commercial operations.
The International Organization for Standardization (ISO) is the world’s largest developer of quality standards. The ISO 13485:2016 Quality Management Standard for Medical Devices is the accepted standard for the design and manufacture of medical devices. The certification is performed by an external Notified Body which performs a two-staged multiple day comprehensive quality system audit to ensure quality and safety standards are met.
The audit was performed at the rHEALTH’s new state-of-art diagnostics facility which was designed and engineered to meet the exacting standards of the Company’s IVD products. The facility includes the latest infrastructure for a high-performing operation, including a full BL2 laboratory, clean hoods, energy efficient systems, electrostatic discharge safe manufacturing areas, laser safety dark rooms, backup power, and additional square footage for expansion.
Eugene Chan, MD, Chairman and CEO of rHEALTH commented: “Together, these new developments give us significant capability to meet our global commercial demands. The certification attests to the high bar of quality and safety our company must meet on a daily basis. The facility supports the rigorous nature of our work. These reflect our organizational culture which has embraced accuracy and reproducibility as being paramount to any diagnostic test.”
About rHEALTH®
rHEALTH is a company focused on the development and commercialization of its Diagnose Yourself, AnywhereTM technology. rHEALTH’s innovations consists of the rHEALTH diagnostic platform, which enables diverse laboratory test classes in a single small volume blood sample intended as a point-of-care solution, the SKYE Sensor, a wireless wearable providing comprehensive real-time vitals monitoring and CHAS, a user-friendly mobile application. For more information, visit www.rhealth.com.
Media Contact
Press Releases, (617) 913-7630, pr@rhealth.com
rHEALTH and COVID-19
Dear Stakeholder,
We want to assure you that we take the health and well-being of our community, customers, and associates very seriously. Like you, we're closely monitoring the quickly developing effects of the Coronavirus (COVID-19) pandemic.
As a diagnostics provider in this time of crisis, we are currently working with the US federal agencies and our partner companies to see how our capabilities may best be leveraged. We remain open and our staff is highly committed to our mission of bringing diagnostics to any setting.
We are all in this together. We will continue to monitor the COVID-19 situation and will follow guidance from public health officials and government agencies, so we can continue to support our communities as needed.
For more information about COVID-19 and what you can do to keep healthy and safe, visit the Centers for Disease Control at cdc.gov or your local health department's website.
Sincerely,
Eugene Chan, MD
CEO
rHEALTH Technology Granted US Patent for Small Volume Blood Handling in Point-of-Care Devices
Invention enables manipulation of small blood samples for accurate point-of-care diagnosis
BEDFORD, Mass., January 9, 2020 – rHEALTH LLC, and its affiliate DNA Medicine Institute, Inc., announced today the issuance of United States Patent Number 10,449,537 titled “Capillary manipulation of clinical samples.” The patent describes a system for collection and delivery of minute blood samples to provide dramatic simplification of clinical diagnoses. One of the major bottlenecks in point-of-care diagnostics is the handling of tiny blood samples from a fingerstick. The 10,449,537 patent describes reliable processing of these blood samples to provide accurate clinical results. The invention allows tests commonly performed in a central lab to be performed in any home or clinical setting.
“This is a seminal patent in our portfolio. The linchpin in blood analysis is accurate blood collection, sampling, and manipulation of minute blood volumes. This patent describes how that is done,” said Dr. Eugene Y. Chan, CEO.
The rHEALTH technology takes a small drop of blood (< 20 µL) and provides results in 15 minutes for a patient or medical provider via its app-driven, Bluetooth connected interface. The technology is backed by NASA for monitoring astronaut crew member health for long-duration space travel. It is designed to bring accurate and comprehensive diagnostic capabilities to places where such testing is unavailable, including homes and other non-traditional settings.
With this latest issuance, the rHEALTH technology has a dozen issued patents that cover sample handling, small blood volume analysis, massive assay multiplexing, and device design. This portfolio confers rHEALTH the unique and sole ability to practice its approach to small volume blood analysis in a legally enforceable manner for 20 years from the initial date of filing of the patents.
About rHEALTH®
rHEALTH is a company focused on the development and commercialization of its Diagnose Yourself, AnywhereTM technology. rHEALTH’s innovations consists of the rHEALTH diagnostic platform, which enables diverse laboratory test classes in a single small volume blood sample intended as a point-of-care solution, the SKYE Sensor, a wireless wearable providing comprehensive real-time vitals monitoring and CHAS, a user-friendly mobile application. For more information, visit www.rhealth.com.
About DNA Medicine Institute
DNA Medicine Institute (DMI) is a biomedical incubator focused on advancing patient care, alleviating human suffering, and treating disease through innovation. Its technology is subject of work funded by NASA, National Institutes of Health, and the Bill & Melinda Gates Foundation. DMI leverages substantial expertise in interdisciplinary science and engineering to solve challenging problems. For more information, visit www.dnamedinstitute.com.
Media Contact
Press Releases, (617) 913-7630, pr@rhealth.com
rHEALTH FVIII Point-of-Care Solution to be Presented at WFH’s 11th Global Forum
Global forum discusses worldwide research, treatment for bleeding disorders, and advancement of patient care
BEDFORD, Mass., November 12, 2019 – rHEALTH LLC will be presenting its transformative Diagnose Yourself, AnywhereTM point-of-care solution for FVIII at the World Federation of Hemophilia (WFH) 11th Global Forum for Research and Treatment Product for Bleeding Disorders. The rHEALTH solution for FVIII is able to take a tiny blood sample (< 20 µL) and provide a result in 15 minutes for a patient or medical provider via its app-driven, Bluetooth connected interface. Conventional central lab FVIII testing require large machines, significant sample preparation, and technician time. Furthermore, results between central labs have a significant discrepancy.
“We are very pleased to be invited by WFH to present our FVIII solution for home and in-office measurement of FVIII levels. Our approach provides a high-level of accuracy for FVIII measurements, particularly for long-acting and gene therapy-based FVIII therapies where conventional testing via activated partial thromboplastin time is less appropriate,” said Dr. Eugene Y. Chan, CEO.
rHEALTH is currently selling its CE-marked FVIII Fluorogenic Assay Kit in English-speaking countries in Europe. This assay is a two-stage assay, similar to the two-stage chromogenic FVIII assay, except that it utilizes a proprietary and highly active, fluorogenic peptide. This approach allows a single range of measurement from < 1% to 200% FVIII levels. The rHEALTH point-of-care solution uses this patent pending two-stage biochemistry to provide high accuracy in measurement of FVIII levels in the presence of interferents such as lupus anti-coagulant and for early detection of inhibitors. The solution is uniquely suitable for patients where such testing is unavailable.
The forum will be in the Westin Hotel in Montreal on November 13-14, 2019 and will address issues related to the safety and supply of treatment products for bleeding disorders, and bring together patient groups, regulators, representatives from industry, and not-for-profit fractionators, as well as doctors who treat people with bleeding disorders. rHEALTH’s talk with be on November 13, 2019 at 3:00 PM EST.
About rHEALTH®
rHEALTH is a company focused on the development and commercialization of its Diagnose Yourself, AnywhereTM technology. rHEALTH’s innovations consists of the rHEALTH diagnostic platform, which enables diverse laboratory test classes in a single small volume blood sample intended as a point-of-care solution, the SKYE Sensor, a wireless wearable providing comprehensive real-time vitals monitoring and CHAS, a user-friendly mobile application. For more information, visit www.rhealth.com.
Media Contact
Rebecca Yu, (617) 913-7630, pr@rhealth.com
rHEALTH ONE Blood Analyzers Delivered to NASA for International Space Station
Blood analyzers to be qualified for spaceflight by NASA’s Commercial-Off-The Shelf (COTS) certification process
CAMBRIDGE, Mass., September 30, 2019 – rHEALTH LLC, and its affiliate DNA Medicine Institute, Inc., today announced that rHEALTH ONE blood analyzers have been delivered to NASA and its prime contractor Zin Technologies for spaceflight qualification. The technology will undergo a rigorous set of tests as outlined in NASA’s International Space Station: Commercial-Off-The-Shelf Certification Process Work Instruction document.
The work instruction outlines the process of proper spaceflight qualification of commercial technologies. The rHEALTH ONE analyzer will be subject to payload verification, safety, and quality tests. The successful certification of the rHEALTH ONE devices will pave the path for a technology demonstration onboard the International Space Station.
“This is an exciting milestone for the rHEALTH technology. We have worked with NASA closely to develop a small volume blood analysis technology for space, with dual-use applications in our homes and diverse medical settings. The technology empowers astronauts and individuals to be able to diagnose themselves, anywhere. We welcome the opportunity to put the technology through its paces, under the most demanding conditions,” said Dr. Eugene Chan, CEO.
The rHEALTH ONE is a small, cytometry-based blood analyzer that uses tiny blood samples (< 10 μL). At 1.5 kg, it weighs less than most laptops and uses minimal power (< 2.5W), drawn from a single USB port. The technology’s critical components, including its optical module and sample loading system, have been successfully tested in zero gravity onboard parabolic flights with NASA. The device analyzes cells and the Company’s nanoscale test strips in a multiplexed manner to provide results in minutes.
About rHEALTH®
rHEALTH is a company focused on the development and commercialization of its Diagnose Yourself, AnywhereTM technology. rHEALTH’s innovations consists of the rHEALTH diagnostic platform, which enables diverse laboratory test classes in a single small volume blood sample intended as a point-of-care solution, the SKYE Sensor, a wireless wearable providing comprehensive real-time vitals monitoring and CHAS, a user-friendly mobile application. For more information, visit www.rhealth.com.
About DNA Medicine Institute
DNA Medicine Institute (DMI) is a biomedical incubator focused on advancing patient care, alleviating human suffering, and treating disease through innovation. Its technology is subject of work funded by NASA, National Institutes of Health, and the Bill & Melinda Gates Foundation. DMI leverages substantial expertise in interdisciplinary science and engineering to solve challenging problems. For more information, visit www.dnamedinstitute.com.
Media Contact
Rebecca Yu, (617) 913-7630, pr@rhealth.com
Abstracts for rHEALTH’s Factor VIII and Platelet Tests Accepted for Poster and Oral Presentations at Upcoming AACC 2019 Meeting
rHEALTH tests to be presented at the industry’s leading annual conference for laboratory medicine
CAMBRIDGE, Mass., July 10, 2019 – rHEALTH LLC, and its affiliate DNA Medicine Institute, Inc., today announced that both of its abstracts have been accepted via peer-review from for the 2019 American Association of Clinical Chemistry (AACC) meeting. The titles and details of the abstracts are as follows:
· Point-of-Care FVIII Test Using an Integrated Microfluidic Consumable with a Fluorogenic Assay, (Poster A-293) on August 6, 2019 at 9:30 AM, Session 07 Hematology and Coagulation
· Point-of-Care Microvolume Cytometer Measures Platelet Counts with High Accuracy from Capillary Blood, Invited Oral Presentation on August 6, 2019 from 2:15 – 2:30 PM
“We are pleased with the acceptance of these abstracts and look forward to sharing our results with the lab medicine community. Our work shows that two very different and complex laboratory tests can be implemented at the point-of-care with high performance using the rHEALTH technology,” stated Dr. Eugene Chan, President and CEO.
A point-of-care FVIII test would allow hemophilia A patients and providers to prevent breakthrough bleeding and early detection of inhibitors. Similarly, an accessible test for platelets can allow proper management of thrombocytopenia, a significant side effect of certain drugs or immune disorders.
The rHEALTH blood sensor technology is an award-winning and patented point-of-care technology that has successfully received funding from the National Aeronautics and Space Administration, National Institutes of Health, and XPRIZE. It is currently the subject of multiple collaborations with academia and biopharmaceutical companies. The technology is designed to analyze blood from fingerpricks and generate results in less than 30 minutes for use by consumers and medical professionals.
The 2019 AACC Annual Scientific Meeting & Clinical Lab Expo is the 71st annual conference of the lab medicine community and expects to have over 20,000 professionals in attendance. It will showcase cutting-edge science and technology and will be held in Anaheim, California, from August 4-8.
About rHEALTH®
rHEALTH is a company focused on the development and commercialization of its Diagnose Yourself, AnywhereTM technology. rHEALTH’s innovations consists of the rHEALTH diagnostic platform, which enables diverse laboratory test classes in a single small volume blood sample intended as a point-of-care solution, the SKYE Sensor, a wireless wearable providing comprehensive real-time vitals monitoring and CHAS, a user-friendly mobile application. For more information, visit www.rhealth.com.
About DNA Medicine Institute
DNA Medicine Institute (DMI) is a biomedical incubator focused on advancing patient care, alleviating human suffering, and treating disease through innovation. Its technology is subject of work funded by NASA, National Institutes of Health, and the Bill & Melinda Gates Foundation. DMI leverages substantial expertise in interdisciplinary science and engineering to solve challenging problems. For more information, visit www.dnamedinstitute.com.
Media Contact
Rebecca Yu, (617) 913-7630, pr@rhealth.com
rHEALTH ONE Technology to be Presented at CYTO 2019
The rHEALTH ONE technology will be presented at CYTO 2019 in Vancouver, Canada on June 23 in a talk titled, “Personal 1.5 kg Microvolume Photon Counting Cytometer for Cell and Biomarker Analysis.” Dr. Chan will be presenting the technology in the Parallel 03: New Technologies Session. The rHEALTH ONE is utilized for small volume analysis of biological, clinical samples in labs and the point-of-care under Research Use Only and under Institutional Review Board clinical studies. The device accommodates flexible samples preparation and measurement of cells and biomarkers with exquisite, multiplexed sensitivity. The device is utilized extensively for assay development in rHEALTH’s IVD Diagnose Yourself, Anywhere efforts.
rHEALTH Nanostrips, Vitals Device, and Fluidics Module to Receive U.S. Patent Protection
Expands patent protection for diagnose yourself, anywhere technology
CAMBRIDGE, Mass., May 21, 2019 -- DNA Medicine Institute, Inc., and its affiliate rHEALTH LLC, today announced that three separate aspects of its technology platform has received a Notice of Allowance and two Issue Notifications from the U.S. Patent and Trademark Office (USPTO). rHEALTH Nanostrips, and their method of multiplexing as described in “Multi-dye microparticles,” is the subject of a USPTO Notice of Allowance. The SKYE Sensor, described in “Multi-channel vitals device,” is U.S. Patent No. 10,251,565. An important rHEALTH ONE subsystem, the “Fluidics module,” is U.S. Patent No. 10,279,347.
"These recent notifications from the USPTO further solidify our focus on protecting core, breakthrough innovations for taking care of patients wherever they may be,” stated Dr. Eugene Chan, President and CEO.
Nanostrips enable vast multiplexing of medically-relevant tests in a small sample volume. Its concept is to shrink traditional test strips so that tens of thousands of different test strips can be in a drop of blood. The SKYE sensor provides comprehensive, continuous vitals capabilities, including measurements of core body temperature. The fluidics module is part of the rHEALTH ONE, a translational research instrument that provides researchers interested in small volume technology flexibility and ease of use in a laboratory setting.
About rHEALTH
rHEALTH is an innovative digital health solutions company focused on creating integrated technologies that fundamentally change how we care for our health. rHEALTH’s innovations consists of the rHEALTH diagnostic platform, which enables diverse laboratory test classes in a single small volume blood sample intended as a point-of-care solution, the SKYE Sensor, a wireless wearable providing comprehensive real-time vitals monitoring and CHAS, a user-friendly mobile application. For more information, visit www.rhealth.com.
About DNA Medicine Institute
DNA Medicine Institute (DMI) is a biomedical incubator focused on advancing patient care, alleviating human suffering, and treating disease through innovation. Its technology is subject of work funded by NASA, National Institutes of Health, and the Bill & Melinda Gates Foundation. DMI leverages substantial expertise in interdisciplinary science and engineering to solve challenging problems. For more information, visit www.dnamedinstitute.com.
rHEALTH Technology Receives Notice of Allowance from US Patent Office for Multiplexed Tests in Small Sample Volumes
This patent enables rHEALTH’s unique technology to measure many analytes in a given small volume sample at home or in the clinic
CAMBRIDGE, Mass., January 23, 2019 /PRWeb/ -- rHEALTH LLC, an innovative digital health solutions company, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 14/682,010, entitled “Microparticle Multiplexing” filed by its affiliate company, DNA Medicine Institute (DMI). This application covers the addition of a length scale to hydrogel microparticles. A Notice of Allowance is a written notification from USPTO that review of the patent application has completed and issuance of the patent is pending. rHEALTH expects the patent to be issued within two months.
“In combination with our US Patent 9,568,425 “Multicoded Analytical Nanostrips,” our technology for highly multiplexed diagnostic tests in small sample volumes now has even broader patent protection,” said Dr. Eugene Y. Chan, Founder and CEO. “The fundamental aspects of this patent enable our unique technology to measure many analytes in a given small volume of sample at home or in the clinic.”
About rHEALTH
rHEALTH is an innovative digital health solutions company focused on creating integrated technologies that fundamentally change how we care for our health. rHEALTH’s innovations consists of the rHEALTH diagnostic platform, which enables diverse laboratory test classes in a single small volume blood sample intended as a point-of-care solution, the SKYE Sensor, a wireless wearable providing comprehensive real-time vitals monitoring and CHAS, a user-friendly mobile application. For more information, visit www.rhealth.com.
About DNA Medicine Institute
rHEALTH’s affiliate, DNA Medicine Institute (DMI) is a biomedical incubator focused on advancing patient care, alleviating human suffering, and treating disease through innovation. Its work is supported by NASA, National Institutes of Health, and the Bill & Melinda Gates Foundation. DMI leverages substantial expertise in interdisciplinary science and engineering to solve challenging problems. For more information, visit www.dnamedinstitute.com.
Media Contact
John Adamou
VP, Corporate & Business Development / Media Relations
(617) 999-8395
pr@rhealth.com
rHEALTH Technology Receives Trademark Approval for RHEALTH®
CAMBRIDGE, Mass., November 7, 2018 -- rHEALTH LLC, an innovative digital health solutions company, announced today that it has been issued a registration certificate by the United States Patent and Trademark Office for use of the trademark, “RHEALTH,” identified with the company’s patient monitoring wearable sensors for diagnosing conditions and capturing key health metrics.
“We are pleased to obtain this trademark approval for RHEALTH which will preserve and protect the equity of this brand in the marketplace,” stated Dr. Eugene Y. Chan, Founder and CEO. “We expect RHEALTH to become a major well-known brand in the digital health space so it is important for us to secure trademark protection for this exciting innovative technology.”
About rHEALTH
rHEALTH is an innovative digital health solutions company focused on creating integrated technologies that fundamentally change how we care for our health. rHEALTH’s innovations consists of the rHEALTH diagnostic platform, which enables diverse laboratory test classes in a single small volume blood sample intended as a point-of-care solution, the SKYE Sensor, a wireless wearable providing comprehensive real-time vitals monitoring and CHAS, a user-friendly mobile application. For more information, visit www.rhealth.com.
Media Contact
John Adamou
Vice President, Corporate & Business Development
and Media Relations
(617) 999-8395
pr@rhealth.com
rHEALTH Technology Receives Notice of Allowance for New U.S. Patent Covering Small Volume Sample Consumable and Loader
CAMBRIDGE, Mass., Oct. 4, 2018 /PRNewswire-iReach/ -- rHEALTH LLC, an innovative digital health solutions company, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 14/645,388, entitled “Sample Consumable and Loader” filed by its affiliate company, DNA Medicine Institute (DMI). This application covers the consumable that carries a microvolume of sample to a sample loader to increase reproducibility of sample loading and offers ease-of-use. A Notice of Allowance is a written notification from USPTO that review of the patent application has completed and issuance of the patent is pending. rHEALTH expects the patent to be issued within two months.
“This Notice of Allowance is an important milestone as we continue to execute against our patent strategy in our effort to develop better care through innovation in portable diagnostic and monitoring technologies”, said Dr. Eugene Y. Chan, Founder and CEO. “The fundamental aspects of this patent enable our consumable technology that carries a small volume of sample possible at point-of-care.”
About rHEALTH
rHEALTH is an innovative digital health solutions company focused on creating integrated technologies that fundamentally change how we care for our health. rHEALTH’s innovations consists of the rHEALTH diagnostic platform, which enables diverse laboratory test classes in a single small volume blood sample intended as a point-of-care solution, the SKYE Sensor, a wireless wearable providing comprehensive real-time vitals monitoring and CHAS, a user-friendly mobile application. For more information, visit www.rhealth.com.
About DNA Medicine Institute
rHEALTH’s affiliate, DNA Medicine Institute (DMI) is a biomedical incubator focused on advancing patient care, alleviating human suffering, and treating disease through innovation. Its work is supported by NASA, National Institutes of Health, and the Bill & Melinda Gates Foundation. DMI leverages substantial expertise in interdisciplinary science and engineering to solve challenging problems. For more information, visit www.dnamedinstitute.com.
Media Contact
John Adamou
Vice President, Corporate and Business Development and Media Relations
(617) 999-8395
pr@rhealth.com
rHEALTH Technology Awarded in NASA’s Civilian Commercialization Readiness Pilot Program (CCRPP)
CAMBRIDGE, Mass., Aug. 20, 2018 -- DNA Medicine Institute, Inc., and its affiliate rHEALTH LLC, a digital health solutions company, today announced that the rHEALTH technology is a subject of NASA’s Civilian Commercial Readiness Pilot Program (CCRPP). Recipients of CCRPP awards must not only demonstrate maturation of technology that aligns with NASA interests, but also strong potential use in markets outside of NASA. This competitive award comes after successful completion of Phase I and Phase II of Small Business Innovation Research (SBIR) and Small Technology Transfer (STTR) Programs.
"We are honored and thrilled to continue our collaboration with NASA to deliver a flight-ready prototype of our unique diagnostic and monitoring technology to the International Space Station,” stated Dr. Eugene Chan, President and CEO.
The main project goal is enabling point-of-patient care in space medicine through delivering portable wireless health solutions—including the rHEALTH small volume blood analyzer and the SKYE Sensor vitals monitor—to astronauts working in the International Space Station.
About rHEALTH
rHEALTH is an innovative digital health solutions company focused on creating integrated technologies that fundamentally change how we care for our health. rHEALTH’s innovations consists of the rHEALTH diagnostic platform, which enables diverse laboratory test classes in a single small volume blood sample intended as a point-of-care solution, the SKYE Sensor, a wireless wearable providing comprehensive real-time vitals monitoring and CHAS, a user-friendly mobile application. For more information, visit www.rhealth.com.
About DNA Medicine Institute
DNA Medicine Institute (DMI) is a biomedical incubator focused on advancing patient care, alleviating human suffering, and treating disease through innovation. Its work is supported by NASA, National Institutes of Health, and the Bill & Melinda Gates Foundation. DMI leverages substantial expertise in interdisciplinary science and engineering to solve challenging problems. For more information, visit www.dnamedinstitute.com.
Media Contact
Lillian Li
(617) 913-7630
pr@rhealth.com